Table 4 The results of specific CTLs of different substances and different effective target ratios in the HPV16, 18 and 58 groups of tumor-bearing mice
From: Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine
Effective target ratio | HPV16 | HPV18 | HPV58 | ||||||
|---|---|---|---|---|---|---|---|---|---|
Vaccine group | AD-NC group | PBS group | Vaccine group | AD-NC group | PBS group | Vaccine group | AD-NC group | PBS group | |
10:1 | 11.678% | 3.857% | 1.867% | 14.682% | 4.509% | 3.031% | 15.381% | 3.115% | 2.501% |
20:1 | 21.201% | 4.840% | 6.798% | 22.871% | 4.509% | 4.906% | 22.807% | 2.277% | 4.105% |
40:1 | 30.160%* | 2.580% | 3.136% | 30.890%* | 4.467% | 5.563% | 33.050%* | 3.102% | 6.168% |